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Summary 
Background Lamotrigine is an anticonvulsant as well as a mood stabiliser. Apart from its established 
use in the treatment of epilepsy, there has been an expansion of its use in the treatment of mental 
disorders. Patients with epilepsy as well as those with mental disorders are at increased risk of 
deliberate drug overdoses. An evidence base for the safety profile of lamotrigine in overdose is an 
essential tool for prescribers. 
Objective To carry out a narrative synthesis of the existing evidence for the safety profile of 
lamotrigine in overdose. 
Methods A systematic search was conducted of EMBASE (1974- December, 2015), MEDLINE (1946-
December, 2015), PsycINFO (1806-December, 2015) and CINAHL (1981-December, 2015) databases. 
Studies were included in which there was a deliberate or accidental single drug overdose of 
lamotrigine, with its toxic effects described.  Studies that did not involve an overdose were excluded. 
A narrative synthesis of the described toxic effects was carried out. 
Results Out of 562 articles identified, 26 studies were included, mainly in the form of case reports 
and series. The most commonly described toxic effects of lamotrigine were on the central nervous 
system, specifically seizures, movement disorders and reduced consciousness. Other toxic effects 
included QTc interval and QRS complex prolongations, hypersensitivity reactions, serotonin 
syndrome as well as rhabdomyolysis possibly due to seizures and/or agitation. Deaths were 
recorded in 2 studies, with cardiovascular and neurological toxic effects described. 
Conclusions Even though lamotrigine has been reported to be well tolerated, there is a risk of toxic 
effects which can be life threatening in overdose. This needs to be borne in mind when prescribing 
to patients at an increased risk of deliberate drug overdose. 
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Introduction 
Lamotrigine [3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine]  a  phenyltriazine derivative inhibits 
high voltage activated-calcium channels [Stefani et al., 1996]  and voltage-sensitive  sodium channels 
as well as reduces neuronal glutamate release. [Biton, 2006] Lamotrigine has effects on the 
serotonergic pathway with re-uptake inhibition, [Sagud et al., 2008] which may explain its 
antidepressant property.  
In terms of pharmacokinetic properties, lamotrigine has 98% bioavailability, with peak 
concentrations (Cmax) reached within 1-3 hours after ingestion. It is 55% protein bound, with an 
apparent volume of distribution (Vd) reported to be 0.9-1.2L/Kg in healthy volunteers and 1.28-
1.36L/Kg in patients who have epilepsy and are on concomitant therapy. It undergoes hepatic 
glucuronidation with a conversion to the inactive 2N-glucuronide metabolite, which is excreted via 
the kidneys. A half-life of 24-30 hours has been reported for lamotrigine when it is used as 
monotherapy, but with multiple dosing it can induce its own metabolism reducing its half-life by 
25%, [Splinter, 2005]  possibly through a weak induction of some phase II enzymes (uridine 
diphosphate glucuronosyltransferases). [Benedetti, 2000] 
The toxic effects of lamotrigine on the central nervous and cardiovascular systems can be explained 
via its action on voltage gated sodium channels, which are responsible for the initiation and 
propagation of action potential in excitable cells such as nerve and muscle cells. [Catterall et al., 
2005] By virtue of its serotonin re-uptake inhibition property, there is a risk of serotonin syndrome 
especially when it is ingested along with other substances that may potentiate this effect. [Kotwal et 
al., 2015] As central nervous system features of serotonin syndrome include: an altered mental state 
which could range from agitation to coma; neuromuscular hyperactivity which can present with a 
variety of features including hyperreflexia, ataxia and nystagmus; and generalized tonic-clonic 
seizures (in severe cases), [Iqbal et al., 2012] the  toxic effects of lamotrigine on the central nervous 
system may also occur through excess serotonin.  
An anticonvulsant hypersensitivity syndrome, which consists of a triad of fever, skin eruption and 
internal organ involvement, [Knowles et al., 1999] has been associated with lamotrigine, despite its 
having a different structure to the aromatic anticonvulsants (phenytoin, phenobarbitone and 
carbamazepine), which have been more commonly associated with the anticonvulsant 
hypersensitivity syndrome.  The exact mechanism for the hypersensitivity syndrome associated with 
lamotrigine is not clear, but it has been reported even with normal doses (100mg) of lamotrigine 
(although in this case, the patient was also receiving valproic acid 1000mg/day as treatment). [Chang 
et al., 2006] 
Lamotrigine has an established role as an anticonvulsant in the treatment of partial, primary 
generalized tonic-clonic seizures and generalized seizures of Lennox-Gestalt syndrome in patients 
aged 2 years or older.[Goldenberg, 2010] In the treatment of mental disorders, benefits of 
lamotrigine have been demonstrated in bipolar depression [Calabrese et al., 1999], as well as in the 
prophylaxis of rapid cycling bipolar disorder. [Calabrese et al., 2000] There is increasing evidence of 
its possible benefits in the control of affective instability and impulsivity [Reich et al., 2009] in 
patients with borderline personality disorder, as well as its benefits in managing  aggression amongst 
this group of patients. [Leiberich et al., 2008] 
 
 
Lamotrigine is reported to be generally well tolerated, with commonly reported adverse effects 
being dizziness, somnolence, nausea, asthenia and headaches in 8 to 20% of patients. [Sabers et al., 
2000]  Rash as a side effect has been reported to develop in about 12% of patients, [Sabers et al., 
2000] with the incidence of serious rashes in bipolar studies reported to be around 0.1%. [Goldsmith 
et al., 2003] Stevens-Johnson syndrome, a severe rash characterized by cutaneous erythema with 
blister formation and mucosal lesions as well as fever, [Mockenhaupt, 2011] has been described to 
occur in 1/1000 lamotrigine treated adults and 1/100 treated children. [Varghese et al., 2006] The 
exact mechanism by which Stevens-Johnson syndrome occurs in some patients treated with 
lamotrigine, is not clear. A molecular target analysis of drugs associated with Stevens-Johnson 
syndrome using a bio-informatics approach, reported the sodium channel alpha 2 (Nav1.2) as a 
target highly associated with Stevens-Johnson. [Burkhart et al., 2015] This voltage gated channel has 
been found to be expressed in keratinocytes present in skin biopsied from patients with painful skin 
conditions such as complex regional pain syndrome type 1. [Zhao et al., 2008] It may play a role in 
the development of Stevens-Johnson syndrome in patients treated with lamotrigine, in view of the 
action of lamotrigine on voltage-gated channels.  
 
Other relatively less common adverse events, which were reported from 12 controlled bipolar 
clinical trials include: dry mouth (6.3%), diarrhea (6.2%) and tremor (3.9%). Data from the bipolar 
clinical trials showed the serious adverse events of mania, hypomania and mixed mania occurred in 
2.5% of 1256 patients treated with lamotrigine, although this was felt to be comparable to the level  
found in patients treated with placebo (2.2% of 1094 patients) and lithium (2.5% of 280 patients). A 
0.5% incidence of these adverse events were felt to be related to lamotrigine in the studies [Seo et 
al., 2011] 
Generally, mental disorders are associated with a relatively increased risk of suicidal behaviour, of 
which self-poisoning has been identified as a common method, accounting for 20.2% (N ≈ 1259) and 
38.2% (N≈ 2381) of female and male suicides respectively, in the United Kingdom in the year 2013. 
[Statistics, 2015] A risk of suicide has also been associated with epilepsy, [Christensen et al., 2007]  
even in the absence of a mental disorder.  Hence patients prescribed lamotrigine may be at higher 
risk of deliberate drug overdose.  
The evidence regarding toxic effects of lamotrigine in overdose is mainly in the form of specific case 
reports, most of which concentrate on a number of specific features related to the case in question. 
In view of the established and increasing use of lamotrigine in groups of patients who are at an 
increased risk of drug overdoses, prescribers are in need of evidence on its safety profile in overdose 
in assessing the risks and benefits of its use.  Hence we carried out a review of the literature in order 
to synthesise the available evidence for the safety profile of lamotrigine in overdose. 
Objectives 
1) To conduct a systematic literature search of the toxic effects of lamotrigine in overdose 
2) To carry out a narrative synthesis of the existing evidence. 
Method 
Search strategy and selection criteria 
 
 
We searched the databases EMBASE (1974-December, 2015), MEDLINE (1946-December, 2015), 
PsycINFO (1806-December, 2015) and CINAHL (1981-December, 2015) for relevant studies in which 
the toxic effects of lamotrigine were described in accidental or deliberate overdose. 
We defined lamotrigine overdose using any of the criteria below: 
1. For patients who were prescribed lamotrigine: lamotrigine taken accidentally or deliberately 
in doses higher than what they were prescribed or intended to take by their prescriber.  
2. For individuals not prescribed lamotrigine:  lamotrigine taken accidentally or deliberately at 
doses which are above the British National Formulary (BNF) recommended (adult 
equivalent) maximum doses for monotherapy (400mg daily for bipolar disorder and up to 
500mg daily for seizures).  
We did not apply any age or language restrictions to our search. A manual search of the references 
of the obtained articles was also carried out for relevant studies. 
We included studies in which there was a deliberate or accidental overdose of lamotrigine, with the 
toxic effects attributable to the drug described.  
We excluded studies in which: 
1.  Lamotrigine was taken at prescribed doses with features of toxicity described.   
2. Lamotrigine was taken at prescribed doses, but its toxicity was precipitated by other co-
prescribed medications. 
3. There were co-ingestants along with lamotrigine. 
Included studies were mainly case reports and case series and hence an assessment of risk of bias 
was not possible. A preliminary search carried out by our team had revealed observational studies as 
the level of evidence available to address the study objectives, with case reports and case series the 
main evidence found, hence a narrative synthesis was planned given the lack of appropriate data to 
conduct meta-analysis. 
Results 
The search revealed a total of 562 records, out of which 26 eligible articles were included in the 
narrative review. Figure 1 shows the study selection process.  Of these 26 articles which represented 
543 individual cases, 21 were case reports, 4 were case series and 1 study had a case control design. 
One of the case series [Lofton et al., 2004] utilised data from 493 single-substance exposures to 
lamotrigine reported to the American association of poison control centers toxic exposure 
surveillance system. Another case series [Moore et al., 2013]  utilised data from 9 patients admitted 
to an inpatient toxicology centre with lamotrigine only overdoses. Whilst only one case in each of 
the other 2 case series, was judged to have met the inclusion criteria and included.  
Table 1 shows the characteristics of the included studies.  
Frequency of toxic effects 
 
 
The study by Lofton and colleagues [Lofton et al., 2004] provided useful information on the 
frequencies of the observed toxic effects of lamotrigine in overdose. In this study of 493 patients, 
the frequencies of the following effects were mentioned: drowsiness/lethargy (20.9%); vomiting 
(11%); nausea (5.1%); ataxia ( 4.9%); dizziness/vertigo (4.5%); tachycardia (4.3%); confusion (2.2%); 
agitation (2.0%); rash  (1.8%); slurred speech (1.8%); tremor (1.8%); nystagmus (1.6%); blurred vision 
(1.4%) and coma  (1.2%).  Seizure as a toxic effect was reported in 8 people (1.6%), with 3 events of 
multiple seizures and 2 individuals with seizures of a status pattern. Respiratory depression was 
reported in 3 patients, whilst cardiac conduction disturbances were reported in 2 patients. 
Described toxic effects of lamotrigine in deliberate overdose 
Central Nervous Effects 
In the studies included in this review, central nervous toxic effects appear to be the most commonly 
associated effect of lamotrigine in overdose. There were 249 individual reports of associated central 
nervous toxic effects in the form of 20 case reports and 4 case series.  
Lamotrigine in overdose was associated with a wide range of central nervous system effects, such as:  
oculogyric crisis, [Veerapandiyan et al., 2011] dystonia, [Eleftheriou et al., 2009] , nystagmus,  ataxia, 
[Buckley et al., 1993, Briassoulis et al., 1998, Daana et al., 2007, Abesamis et al., 2010, Lapoint et al., 
2010, Strimel et al., 2010, Hajiali et al., 2015] slurred speech [Hajiali et al., 2015] and hypertonia. 
[Buckley et al., 1993] Abnormal movements with intermittent jerking, choreo-athetoid movements, 
[Chiew et al., 2013]  and choreiform dyskinesia [Miller et al., 2008] have been described in case 
reports.  
Paradoxically, lamotrigine which is an anticonvulsant has been associated with seizures in overdose.  
[Waring, 2009, French et al., 2011] The seizures associated with lamotrigine have occurred in 
patients without a documented prior history of seizures [Lapoint et al., 2010, French et al., 2011] 
and in patients with a history of seizures. [Dinnerstein et al., 2007, Waring, 2009, Algahtani et al., 
2014] The seizures have been described as generalized, [Thundiyil et al., 2007] with specific seizure 
types reported with single drug overdoses of Lamotrigine being: tonic-clonic seizures [Briassoulis et 
al., 1998, Daana et al., 2007, Dinnerstein et al., 2007, Willis et al., 2007, Waring, 2009, Abesamis et 
al., 2010, Lapoint et al., 2010, French et al., 2011, Nogar et al., 2011, Hajiali et al., 2015] and 
myoclonic seizures. [Lapoint et al., 2010]. The tonic-clonic  seizures were reported  along with  the 
clinical findings of clonus and hyperreflexia [Nogar et al., 2011] in a case, and status epilepticus 
developing in another case. [Chavez et al., 2015] ) The myoclonic seizures were described as a 
generalized myoclonic status epilepticus [Algahtani et al., 2014] in a report.  
Reduced levels of consciousness (without an associated description of seizures) have been reported 
in single drug overdoses of Lamotrigine. [Zidd et al., 2004, Castanares-Zapatero et al., 2012]  
An encephalopathic picture which included an agitated delirium, mutism, nystagmus, upper motor 
neurone features as well as catatonia was described in a 40-year-old woman, with a previous history 
of glioblastoma multiforme and seizures, who took thirty 200mg tablets (6000mg) of the extended- 
release (XR) preparation of lamotrigine. [Hernandez et al., 2010] 
Two patients in a case series from an inpatient toxicology centre [Moore et al., 2013] were reported 
to have met the Hunter criteria [Dunkley et al., 2003] for serotonin syndrome. One of these patients 
 
 
was a 1year old child with a serum lamotrigine level of 18mg/l (taken at 8hours), who had presented 
with agitation, diaphoresis and an inducible clonus. All 9 patients in this case series were reported 
have had altered mental states: with 4 patients having a depressed mental state; 5 patients having 
an agitated mental state and 3 patients having both depressed and agitated mental states. 5 of the 
patients in the series had hyperreflexia and intermittent myoclonus. 
Cardiac Effects 
There were 36 individual reports of associated cardiac toxic effects; these were in the form of 6 case 
reports, 2 case series and 1 case control study. 
Widening of the QRS complexes in association with lamotrigine overdose, has been reported in a 
patient who had a normal heart rate of 88b/min, but with a Left Bundle branch block ECG pattern. 
[Castanares-Zapatero et al., 2012] A widening of the QRS complex of up to 210ms has also being 
associated with a tachycardia, with outcomes of this being complete heart block [French et al., 2011] 
and a pulseless ventricular tachycardia. [Nogar et al., 2011]. Sinus tachycardia as a nonspecific 
finding without a description of QRS complex widening, has also been reported.[Thundiyil et al., 
2007]  
Chavez and colleagues [Chavez et al., 2015] described a male patient who developed a new onset 
right bundle branch block, with the prolongation of QRS interval (up to 128ms) and QTc intervals (up 
to 458ms). Much longer QTc prolongations (up to 586ms) were described in a case series study.  
[Moore et al., 2013] Prolongation of QTc intervals as a toxic effect of lamotrigine in overdose was 
examined  further in a case control study; [Hodson et al., 2009]  even though the QTc interval was 
found to be longer in the lamotrigine overdose group compared to the control group, the difference 
between the groups was not statistically significant (P=0.137). However this was a small study with 
18 cases.  
A brugada-like ECG pattern has been described in an adult patient who had a serum lamotrigine 
level of 20.4mg/l. [Strimel et al., 2010]   
Other described toxic effects 
A range of other features of toxicity have been described in the course of a lamotrigine overdose, 
including nausea, vomiting, vertigo, lethargy, respiratory depression. [Lofton et al., 2004] 
Headaches, diplopia, dizziness, sweating and abdominal pain [Hajiali et al., 2015] were other 
described features which appeared to have preceded the onset of a tonic-clonic seizure in a patient. 
Abnormal vital sign readings were stated in some of the reports, these included: tachypnea with 
recorded respiratory rates of up to 32 breaths per minute; [Hajiali et al., 2015]  tachycardia with 
heart rates up to 131 beats/min ; [Nogar et al., 2011] elevated blood pressure readings of up to 
185/95mmHg [Hajiali et al., 2015] and pyrexia with a temperature above 38oC. [Moore et al., 2013]   
Rhabdomyolysis has been reported in the context of lamotrigine overdose, although this might have 
been the consequence of the associated seizure [French et al., 2011]or agitation.  
Mylonakis and colleagues [Mylonakis et al., 1999] described  a hypersensitivity-like syndrome with 
low grade pyrexia, erythema and oedema involving the periorbital region, leucocytosis, elevated 
 
 
phosphokinase (7222 units/L), elevated alanine aminotransferase (76units/l), elevated aspartate 
aminotransferase (154units/l) and a raised creatinine (24mg/l) in a 49-year-old man, who 
inadvertently received 4 daily doses of 2700mg of lamotrigine.  
Hajiali and colleague [Hajiali et al., 2015] described menorrhagia of a 2 day duration observed in a 26 
year old who was reported to have taken up to 40grams of Lamotrigine. The patient was reported to 
have had a normal gynaecological examination at the time. Her menstrual periods were reported to 
have been normal prior to this. Apart from the drop in the patient’s haemoglobin levels, 
investigations carried out in this patient were reported to be normal, although no specific mention 
was made of whether the investigations involved coagulation tests. 
Rash, a common and important adverse reaction in normal doses, has also been described in two 
case reports of lamotrigine overdose. A flat, lacy, reticular blanching rash occurred along with a 
transient mild derangement of liver function tests in a 3-year-old who accidentally ingested up to 
1150mg of lamotrigine. [Zidd et al., 2004] A diffuse, discrete confluent, branching red maculo-
papular rash without mucosal involvement was described in the context of lamotrigine overdose 
presenting with a hypersensitivity like syndrome. [Mylonakis et al., 1999] 
Death 
Death occurring in the course of lamotrigine overdose was well described in 2 separate case reports. 
French and colleagues [French et al., 2011]  described a case of a 19-year-old patient who took 
4000mg of lamotrigine.  Events following the overdose had involved the development of seizures 
and a cardiac arrest. The patient subsequently developed a respiratory and metabolic acidosis as 
well as cardiac arrhythmias including complete heart block. He developed an acute renal failure, 
which was felt to be due to rhabdomyolysis with a recorded CK of over 23000 U/L. A bacterial 
pneumonia infection (with Staphylococcus and Klebsiela) and a disseminated intravascular 
coagulation occurred prior to his death.  
Nogar and colleagues [Nogar et al., 2011] described a 48-year-old man who ingested 7500mg of 
lamotrigine, who developed a tonic-clonic seizure and subsequently developed a broad complex 
tachycardia which became pulseless, with a resulting anoxic brain injury and death four days later. 
Both overdoses were solitary drug overdoses of Lamotrigine. 
Discussion 
Lamotrigine taken in overdose is not always associated with toxic effects. In the case series of 493 
patients [Lofton et al., 2004] who ingested lamotrigine as a single substance overdose,  the majority 
(52.1%) did not experience any toxic effects, and there were no deaths. However, a study using a 
calculated Shannon information index to compare requirements for interventions in overdoses of 
newer anticonvulsants, reported lamotrigine as the most toxic in overdose by this definition,  [Wills 
et al., 2014] compared to gabapentin, levetiracetam , pregabalin, tiagabine, topiramate and 
oxcarbazepine. 
In this review, reported single-agent overdoses of lamotrigine with doses of 100-40000mg and 
serum concentrations of 15.5-74.7mg/l, have been associated with a wide variety of toxic effects on 
 
 
the central nervous and cardiovascular systems, as well as hypersensitivity like syndrome. Figure 1 
shows mechanisms for the toxic actions of lamotrigine on the body. Toxicity has been correlated 
with increasing serum lamotrigine levels in some [Froscher et al., 2002, Hirsch et al., 2004] but not 
all studies. [Kilpatrick et al., 1996] In view of the available evidence in this review for the toxic effects 
of lamotrigine being mainly case reports and case series, it was not possible to calculate a minimum 
dose or serum concentration associated with toxic effects.  
Treatment of lamotrigine toxicity is largely based on the observed clinical effects, and may involve 
the use of measures to prevent further absorption of the ingested lamotrigine such as use of 
activated charcoal and gastric lavage.  
There has been a recommendation for the use of alkalinisation via sodium bicarbonate when 
cardiotoxicity due to sodium channel blockade is suspected, [Castanares-Zapatero et al., 2012] which 
is similar to its suggested use in the management of tricyclic antidepressant toxicity. [Newton, 2015] 
In view of lamotrigine’s lipophilic properties, use of intravenous lipid emulsion has been suggested 
as a potential treatment strategy in cases of cardiac toxicity in the context of sodium channel 
blockade, if refractory to alkalinisation therapy. [Castanares-Zapatero et al., 2012] The exact 
mechanism by which lipid emulsion therapy works is not entirely clear. It has been suggested that 
lipid emulsion therapy may work by creating a “lipid sink” [Weinberg et al., 1998] in the blood 
stream, which draws in a lipophilic substance thereby reducing the plasma aqueous concentration of 
the substance. It may also work by increasing the cardiac energy supply by improving fatty acid 
metabolism [Picard et al., 2006] or by activation of calcium channels, [Castanares-Zapatero et al., 
2012] thereby increasing the inotropic action.[Chavez et al., 2015] In a case report, there was a 
narrowing of a previously widened QRS complex and a normalisation of conduction interval 
disturbances, a few minutes after the initial bolus of lipid emulsion therapy was administered to a 
patient whose ECG had showed no response to sodium bicarbonate therapy. [Castanares-Zapatero 
et al., 2012]  As the toxic effect of lamotrigine on the central nervous system can also be explained 
via sodium channel blockade [Catterall et al., 2005], the criteria for the use of lipid emulsion therapy 
would include life- threatening cardiac and/or neurologic toxicity refractory to conventional therapy. 
Prompt and effective management of seizures is required, with parenteral benzodiazepines 
recommended as the first line treatment for drug induced seizures, and barbiturates or propofol  
recommended as second line anticonvulsants. It is felt propofol may have a synergistic effect when 
used with benzodiazepines or barbiturates. [Chen et al., 2016] Sedation with benzodiazepines may 
also play an important role in the management of features that may occur with a serotonin 
syndrome, Such as: anxiety, agitation, increased muscular activity, tremors, hypertension, 
tachycardia and pyrexia. [Dvir et al., 2008, Iqbal et al., 2012, Volpi-Abadie et al., 2013] 
The Strategies for managing lamotrigine overdose are summarized in Table 1. 
The role for haemodialysis in lamotrigine overdose has been considered. Using a 100mg dose of 
lamotrigine in a study of the pharmacokinetics of lamotrigine in renal impairment, haemodialysis 
was reported to have shortened the elimination half-life from 59.6 +/- 28.1 hours during the 
interdialysis period to 12.2 +/- 6.4 hours during the dialysis period, with 17% of the drug extracted 
by haemodialysis. [Fillastre et al., 1993] Lu and colleagues [Lu et al., 2012] described a reduction in 
the serum concentration of lamotrigine from 61.2 mg/l to 7.2mg/l over a 62 hour period using blood 
perfusion which involved haemodialysis and haemoperfusion. Taking into consideration its half- life  
 
 
and a potential to induce its own metabolism, [Splinter, 2005] it was difficult to assess the role of 
haemodialysis in this instance. Further studies are required to clarify the role (if any) of 
haemodialysis in the management of lamotrigine overdose. 
In conclusion, even though lamotrigine has been reported to be well tolerated at normal doses (and 
even in some overdoses), there is evidence of clinically important toxicity in overdose, with variable 
outcomes; this may be a complete recovery occurring in majority of the cases, but death has been 
reported.  Its toxic profile must be considered when prescribing lamotrigine to patients who are 
potentially at an increased risk of taking overdoses.  This should form part of the risk-benefit analysis 
particularly in the drug’s longer term and increasing use in psychiatric populations, when weighed 
against alternative mood stabilisers. There is a paucity of systematic observational studies for the 
toxic effects of lamotrigine in overdose, with only one case control study found and included in this 
study. Hence frequencies of specific toxic effects could be judged from this single study alone.  There 
remains a need for more systematic evidence for the toxic effects of lamotrigine in overdose, in the 
form of case control studies as well as retrospective cohort studies, which can help confirm a direct 
association between the observed toxic effects and the overdose, including the consideration that 
some of the observed effects may well be indirect effects, with the triggering event being the 
overdose. 
 
 
Limitations 
Due to the nature of the review, only evidence in the form of observational studies (mainly case 
reports) was available. We sought to follow the principles of the PRISMA reporting guideline, [Moher 
et al., 2009] but this was limited by the absence of quantitative studies; for instance there was no 
risk of bias assessment we could conduct. Although we did not place a language restriction on our 
search criteria and on the included studies, we were not able to include one of the obtained articles 
in this review, due to our inability to translate its full text from Farsi to English language. 
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Associated Effect of lamotrigine overdose Management 
All effects 
(Central Nervous System Effects  
Cardiac Effects 
Nausea 
Vomiting) 
Treatment is based on observed clinical effects 
and may involve: 
 Maintenance and support of the 
airway, breathing and circulation 
 Measures to prevent further absorption  
e.g use of activated charcoal use, 
gastric lavage 
 Benzodiazepines for seizures, increased 
muscular activity, tremors, agitation, 
anxiety, hypertension, tachycardia 
 Antiemetics if indicated 
 
Life threatening cardiac effect including 
arrhythmias, widened QRS intervals,  QTc 
interval prolongation 
General measures as above and 
Alkalinisation using Sodium Bicarbonate as an 
infusion. 
If symptoms fail to respond to above measures 
then consider Lipid emulsion therapy 
Life threatening neurologic features General measures as above and 
Use of phenobarbitone &/ propofol for 
refractory seizures 
Alkalinisation using Sodium Bicarbonate as an 
infusion. 
If symptoms fail to respond to above measures 
then consider Lipid emulsion therapy 
Hypersensitivity reactions General measures above as appropriate 
Use of antihistamines and steroids as 
appropriate 
 
Table 1: General principles for the management of Associated Effects of lamotrigine Overdose
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conduction/ 
action potential 
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Fig 1 : Mechanisms of the toxic effects of Lamotrigine in overdose, on the human body 
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 Authors Year of 
publicati
on 
Study 
design/type 
Age of  
patient 
Dose of ingested 
Lamotrigine if 
stated 
Stated Serum 
Concentration (No 
of hours after 
ingestion) 
 Feature of toxicity included in narrative synthesis 
1 [Lofton et al., 
2004] 
2004 Case series, 
with 493 
exposures to 
Lamotrigine 
identified 
40.2% were 
between 20-
59years. 35.4% 
were less than 
4 years old 
Variable doses Not stated Drowsiness(20.9%), vomiting(11%),nausea(5.1%),  
ataxia(4.9%), vertigo(4.5%),  tachycardia(4.3%), 
rash(1.8%), tremor(1.8%) and respiratory 
depression (N=3).   52.1% had no toxic features. 
2 [Veerapandiyan 
et al., 2011] 
2011 Case series-
Only one 
report met 
the inclusion 
criteria 
25 years 1600mg Not stated, but the 
mean for the 
series was 
15.5mg/l 
Oculogyric crisis. 
3 [[Eleftheriou et 
al., 2009] 
2009 Case report 45years 8400mg 40 mg/l (Time 
after ingestion not 
stated) 
Acute dystonia. 
4  [Buckley et al., 
1993] 
1993 Case report 26 years 1350mg 17.4mg/l (3 hrs)  Hypertonia, nystagmus and ataxia. 
5 [Briassoulis et 
al., 1998] 
1998 Case report 2 years old 800mg(weight of 
child not stated) 
3.8mg/l (≈2hrs) Generalized tonic-clonic seizures, severe ataxia. 
 
 
 Authors Year of 
publicati
on 
Study 
design/type 
Age of  
patient 
Dose of ingested 
Lamotrigine if 
stated 
Stated Serum 
Concentration (No 
of hours after 
ingestion) 
 Feature of toxicity included in narrative synthesis 
6 [Daana et al., 
2007] 
2007 Case report 2 years  
(weight 20kg) 
500mg (25mg/kg) Not done Generalized tonic-clonic seizures. 
7 [Abesamis et al., 
2010] 
2010 Case report  20 months 
(weight not 
stated) 
1500mg 30.5mg/l ( Time 
after ingestion not 
stated) 
Ataxic gait, tonic-clonic activity. 
8 [Lapoint et al., 
2010] 
2010 Case report  13 months 800mg 31.1mg/l (3 hrs) Nystagmus, ataxia, tonic-clonic activity, myoclonic 
seizure. 
9 [Strimel et al., 
2010] 
2010 Case report 22 years Not clear 20.4mg/l (Time 
after ingestion not 
stated) 
Brugada-like ECG pattern, mild ataxia. 
10 [Hajiali et al., 
2015] 
2015 Case report 26 years 40000mg ≈73mg/l (2 days-
exact number of 
hours uncertain) 
Headaches, diplopia, sweating, ataxia, nystagmus, 
tonic-clonic seizures. Tachycardia. Menorrhagia. 
 
  
11 [Chiew et al., 
2013]] 
2013 Case 
series(2)-
only 1 report 
included 
18 months       
( 9kg) 
100mg(11.1mg/kg) ≈30.3mg/l*       
(Time after 
ingestion not 
stated)  
Intermittent jerking, choreo-athetoid movements. 
 
 
 Authors Year of 
publication 
Study 
design/type 
Age of  
patient 
Dose of ingested 
Lamotrigine if 
stated 
Stated Serum 
Concentration (No 
of hours after 
ingestion) 
 Feature of toxicity included in narrative synthesis 
12 [Miller et al., 
2008] 
2008 Case report 23 years “All his tablets” 63.9mg/l (Time 
after ingestion not 
stated)   
Choreiform dyskinesia. 
13 [Waring, 2009, 
Moore et al., 
2013] 
2009 Case report 42 years Unknown 30mg/l ( 1.3 hrs) Tonic-clonic seizure. 
14 [French et al., 
2011] 
2011 Case report 19 years 4000mg 37.5mg/l (19 hrs) Generalized tonic-clonic seizure, QRS widening 
(214ms), complete heart block, death. 
15 [Dinnerstein et 
al., 2007] 
2007 Case report 42 years 4100mg 47.4mg/l (Time 
after ingestion not 
stated) 
Secondarily generalized tonic-clonic seizures. 
16 [Algahtani et 
al., 2014] 
 
2014 Case report 46  years 6000mg ≈ 25.6mg/l*  ( time 
after ingestion 
unclear) 
Generalized myoclonus status epilepticus. 
17 [Thundiyil et 
al., 2007] 
2007 Case report 19 month old Unknown 20.3mg/l (1 hrs) Generalized seizures, sinus tachycardia. 
18 [Willis et al., 
2007] 
2007 Case report 12 day old Unknown 35mg/l (unclear) Tonic-clonic seizure. 
 
 
 
  
 
 
 Authors Year of 
publication 
Study 
design/type 
Age of  
patient 
Dose of ingested 
Lamotrigine if 
stated 
Stated Serum 
Concentration (No 
of hours after 
ingestion) 
 Feature of toxicity included in narrative synthesis 
19 [Nogar et al., 
2011] 
2011 Case report 48 years 7500mg 74.7mg/l (Time 
after ingestion not 
stated) 
Tonic-clonic seizures. Wide complex tachycardia, which 
became pulseless. Death. 
20 [Chavez et al., 
2015] 
2015 Case report 36 years 13500mg 78mg/l (2 hrs) Tonic-clonic seizures, status epilepticus. 
21 [Zidd et al., 
2004] 
2004 Case report 3 years (weight 
= 15mg) 
1150mg 
(76.7mg/kg) 
25.3mg/l              
(1.3hrs)  
Rash, transient (mild) derangement of liver function 
tests, sedation. 
22 [Castanares-
Zapatero et al., 
2012] 
2012 Case report 50 years 3500mg 29.7mg/l (6hrs) Reduced Glasgow coma score (GCS of 6) 
Left bundle branch ECG pattern. 
23 [Hernandez et 
al., 2010] 
2010 Case report 40 years 6000mg 49.5mg/l (5 days-
exact number of 
hours uncertain) 
Agitated delirium, mutism and catatonia. 
24 [Hodson et al., 
2009] 
2009 Case control 
study (with 
18 cases) 
Median age 
39years (range 
19-60years) 
Median ingested 
dose= 750mg 
(range 200-
5600mg) 
Not stated Mean difference in QTc between lamotrigine overdose 
group and controls was 15.3ms (P=0.137). 
 Authors Year of 
publication 
Study 
design/type 
Age of  Dose of ingested 
Lamotrigine if 
Stated Serum 
Concentration (No 
of hours after 
 Feature of toxicity included in narrative synthesis 
 
 
patient stated ingestion) 
25 [Moore et al., 
2013] 
2013 Case Series 
(of 9 
patients)  
Age ranged 
from 1year to 
57years old 
 Stated amounts 
ranged from 
400mg(≈35mg/kg) 
to 13500mg 
Stated 
concentrations 
Include: 
 
26mg/l (3 hrs) 
17.8mg/l (6hrs) 
18mg/l (8 hrs) 
90mg/l (16.7hrs) 
Serotonin syndrome, altered mental states, 
hyperreflexia, myoclonus, prolonged QTc interval, 
pyrexia. 
26 [Mylonakis et 
al., 1999] 
1999 Case report 49 years  2700mg daily for 
4 days 
Not stated Facial oedema, maculo-papular rash, leucocytosis, 
hepatitis and acute renal failure. 
 * 1mg/l = 3.9umol/l [Patsalos P, 2014]  
Table 2: Characteristics of included studies  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Study selection process 
 
562 records screened 
50 potentially relevant 
records screened 
26 articles included in 
narrative data synthesis 
512 records excluded on the basis 
of title and abstract  
22 Duplicates removed 
28 full text articles 
assessed for eligibility 
2 of the case series which had different 
titles and publication dates, were found 
to be similar, hence one of them was 
excluded 
One of obtained articles which had 
its full text in Persian language, was 
difficult to get translated, hence it 
was excluded 
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